BACKGROUND: In 2012, over 240,000 men were diagnosed with prostate cancer and over 28,000 died from the disease. Animal models of prostate cancer are vital to understanding its pathogenesis and developing therapeutics. Canine models in particular are useful due to their similarities to late-stage, castration-resistant human disease with osteoblastic bone metastases. This study established and characterized a novel canine prostate cancer cell line that will contribute to the understanding of prostate cancer pathogenesis. METHODS: A novel cell line (Probasco) was derived from a mixed breed dog that had spontaneous prostate cancer. Cell proliferation and motility were analyzed in vitro. Tumor growth in vivo was studied by subcutaneous, intratibial, and intracardiac injection of Probasco cells into nude mice. Tumors were evaluated by bioluminescent imaging, Faxitron radiography, µCT, and histology. RT-PCR and genome-wide DNA copy number profiling were used to characterize the cell line. RESULTS: The Probasco cells grew in vitro (over 75 passages) and were tumorigenic in nude mice. Probasco cells expressed high levels of BMP2, CDH1, MYOF, FOLH1, RUNX2, and SMAD5 modest CXCL12, SLUG, and BMP, and no PTHrP mRNA. Following intracardiac injection, Probasco cells metastasized primarily to the appendicular skeleton, and both intratibial and intracardiac injections produced osteoblastic tumors in bone. Comparative genomic hybridization demonstrated numerous DNA copy number aberrations throughout the genome, including large losses and gains in multiple chromosomes. CONCLUSIONS: The Probasco prostate cancer cell line will be a valuable model to investigate the mechanisms of prostate cancer pathogenesis and osteoblastic bone metastases.
BACKGROUND: In 2012, over 240,000 men were diagnosed with prostate cancer and over 28,000 died from the disease. Animal models of prostate cancer are vital to understanding its pathogenesis and developing therapeutics. Canine models in particular are useful due to their similarities to late-stage, castration-resistant human disease with osteoblastic bone metastases. This study established and characterized a novel canineprostate cancer cell line that will contribute to the understanding of prostate cancer pathogenesis. METHODS: A novel cell line (Probasco) was derived from a mixed breed dog that had spontaneous prostate cancer. Cell proliferation and motility were analyzed in vitro. Tumor growth in vivo was studied by subcutaneous, intratibial, and intracardiac injection of Probasco cells into nude mice. Tumors were evaluated by bioluminescent imaging, Faxitron radiography, µCT, and histology. RT-PCR and genome-wide DNA copy number profiling were used to characterize the cell line. RESULTS: The Probasco cells grew in vitro (over 75 passages) and were tumorigenic in nude mice. Probasco cells expressed high levels of BMP2, CDH1, MYOF, FOLH1, RUNX2, and SMAD5 modest CXCL12, SLUG, and BMP, and no PTHrP mRNA. Following intracardiac injection, Probasco cells metastasized primarily to the appendicular skeleton, and both intratibial and intracardiac injections produced osteoblastic tumors in bone. Comparative genomic hybridization demonstrated numerous DNA copy number aberrations throughout the genome, including large losses and gains in multiple chromosomes. CONCLUSIONS: The Probasco prostate cancer cell line will be a valuable model to investigate the mechanisms of prostate cancer pathogenesis and osteoblastic bone metastases.
Authors: K K Cornell; D G Bostwick; D M Cooley; G Hall; H J Harvey; M J Hendrick; B U Pauli; J A Render; G Stoica; D C Sweet; D J Waters Journal: Prostate Date: 2000-10-01 Impact factor: 4.104
Authors: George R Schade; Jill Keller; Kim Ives; Xu Cheng; Thomas J Rosol; Evan Keller; William W Roberts Journal: J Urol Date: 2012-09-20 Impact factor: 7.450
Authors: Joseph R Osborne; Naveed H Akhtar; Shankar Vallabhajosula; Alok Anand; Kofi Deh; Scott T Tagawa Journal: Urol Oncol Date: 2012-05-31 Impact factor: 3.498
Authors: Thomas J Rosol; Sarah H Tannehill-Gregg; Bruce E LeRoy; Stefanie Mandl; Christopher H Contag Journal: Cancer Date: 2003-02-01 Impact factor: 6.860
Authors: Melani A M Fork; Hugo Murua Escobar; Jan T Soller; Katharina A Sterenczak; Saskia Willenbrock; Susanne Winkler; Martina Dorsch; Nicola Reimann-Berg; Hans J Hedrich; Jörn Bullerdiek; Ingo Nolte Journal: BMC Cancer Date: 2008-08-15 Impact factor: 4.430
Authors: Said M Elshafae; Wessel P Dirksen; Aylin Alasonyalilar-Demirer; Justin Breitbach; Shiyu Yuan; Noriko Kantake; Wachiraphan Supsavhad; Bardes B Hassan; Zayed Attia; Lucas B Alstadt; Thomas J Rosol Journal: Prostate Date: 2020-04-29 Impact factor: 4.104
Authors: J K Simmons; B E Hildreth; W Supsavhad; S M Elshafae; B B Hassan; W P Dirksen; R E Toribio; T J Rosol Journal: Vet Pathol Date: 2015-05-28 Impact factor: 2.221
Authors: Nicole A Kohart; Said M Elshafae; Aylin A Demirer; Wessel P Dirksen; Justin T Breitbach; Sherry T Shu; Jingyu Xiang; Katherine N Weilbaecher; Thomas J Rosol Journal: Leuk Lymphoma Date: 2019-10-08
Authors: H Thiemeyer; L Taher; J T Schille; L Harder; S O Hungerbuehler; R Mischke; M Hewicker-Trautwein; Z Kiełbowicz; B Brenig; E Schütz; J Beck; H Murua Escobar; I Nolte Journal: Sci Rep Date: 2019-09-13 Impact factor: 4.379
Authors: Nicole A Kohart; Said M Elshafae; Wachirapan Supsahvad; Aylin Alasonyalilar-Demirer; Amanda R Panfil; Jingyu Xiang; Wessel P Dirksen; Deborah J Veis; Patrick L Green; Katherine N Weilbaecher; Thomas J Rosol Journal: J Bone Oncol Date: 2019-08-20 Impact factor: 4.072